BioStock: BioInvent’s CEO expects eventful 2023

During 2022, biotech company BioInvent showed proof of attracting capital as well as new collaborations. The company also advanced several pipeline projects. BioInvent has thus entered 2023 with strong positioning, and several clinical updates are expected for the year. BioStock spoke with CEO Martin Welschof to find out what the year will mean for the company.

Read the article about BioInvent at biostock.se:

https://www.biostock.se/en/2023/03/bioinvents-ceo-expects-eventful-2023

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/